Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
The Korean Journal of Hepatology ; : 263-277, 2010.
Artículo en Inglés | WPRIM | ID: wpr-103213

RESUMEN

Treatments for chronic hepatitis C has evolved significantly in the past 15 years. The standard of care (SOC) is peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks in patients infected with HCV genotype 1 or 2/3, respectively. The treatment duration can be individualized based on the baseline viral load and the speed of the virologic response during treatment. However, current therapies are associated with side effects, complications, and poor patient tolerability. Therefore, there is an urgent need to identify better strategies for treating this disease. An improved sustained virologic response (SVR) can be achieved with new HCV-specific inhibitors against NS3/4A and NS5B polymerases. Recent trials have found SVR rates in patients with HCV genotype 1 infection of 61~68% and 67~75% for combining the SOC with the protease inhibitors telaprevir and boceprevir, respectively. Several new HCV-specific inhibitors such as protease inhibitors and nucleoside and non-nucleoside polymerase inhibitors as well as non-HCV-specific compounds with anti-HCV activity are currently in clinical evaluation. In this review we discuss these new treatments for chronic hepatitis C.


Asunto(s)
Humanos , Antivirales/uso terapéutico , ARN Polimerasas Dirigidas por ADN/antagonistas & inhibidores , Hepatitis C Crónica/tratamiento farmacológico , Interferones/uso terapéutico , Nucleótidos/química , Inhibidores de Proteasas/uso terapéutico , Proteínas no Estructurales Virales/antagonistas & inhibidores , Internalización del Virus/efectos de los fármacos
2.
Southeast Asian J Trop Med Public Health ; 2001 Dec; 32(4): 776-8
Artículo en Inglés | IMSEAR | ID: sea-35111

RESUMEN

The result of initial treatment with amphotericin B (0.7 mg/kg/day) plus rifampin (600 mg/day) for 2 weeks, followed by fluconazole (400 mg/day) for 8 weeks in the acute treatment of cryptococcal meningitis in AIDS is reported. There were 10 patients in the study: at 2 weeks, all had made a clinical response and cerebrospinal fluid was sterile in 4 patients; at 10 weeks, all had negative cerebrospinal fluid cultures. Serious side effects were not detected.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Adulto , Anfotericina B/administración & dosificación , Antifúngicos/administración & dosificación , ARN Polimerasas Dirigidas por ADN/antagonistas & inhibidores , Quimioterapia Combinada , Inhibidores Enzimáticos/administración & dosificación , Femenino , Humanos , Masculino , Meningitis Criptocócica/tratamiento farmacológico , Rifampin/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA